|
|
|
|
| LEADER |
03139nam a22004335i 4500 |
| 001 |
978-3-642-74615-4 |
| 005 |
20191024151709.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121227s1989 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783642746154
|
| 024 |
7 |
|
|a 10.1007/978-3-642-74615-4
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Drug Research and Drug Development in the 21st Century
|b Science and Ethics /
|c edited by H.P. Wolff, A. Fleckenstein, Egon O. Philipp.
|
| 250 |
|
|
|a 1st ed. 1989.
|
| 260 |
# |
# |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 1989.
|
| 300 |
|
|
|a XII, 310 p. 14 illus.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Bayer AG Centenary Symposium,
|
| 505 |
0 |
|
|a History and Philosophy of Bayer Pharmaceutical Research -- Science, Responsibility, and Society -- Opening Remarks -- Message of Greeting -- I. Unresolved Problems of Chronic Diseases -- Demographic and Epidemiologic Trends Today -- Atherosclerosis and Coronary Heart Disease -- Rheumatoid Arthritis: A Modell of Chronic Inflammation -- Alzheimer’s Disease -- Obstructive Lung Disease -- Biological Approaches to Cancer Therapy -- Challenges and Obstacles hi Clinical Evaluations of Therapy -- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials -- The Impact of Clinical Trials on Clinical Practice -- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics -- II. Advanced Technologies, Scientific Achievements -- Receptors and Messengers -- Low Density Lipoproteins and Hypercholesterolemia -- Leukotrienes in Airways and Blood Vessels -- Drug Design -- Opening Remarks -- Thoughts About Gene Regulation and Mammalian Development -- Protein Crystallography and Drug Design -- Applying Engineering Principles to the Design of Cellular Biology -- Analytical Pathophysiology and Biochemistry -- Opening Remarks -- Neurotransmitters in the Brain -- Mechanisms of Cancer Metastasis -- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing -- The Patient as a Subject to Medical Research -- Ethics of Drug Research and Drug Development -- The Functions of Ethical Committees -- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development -- The Quality of Life of Hypertensive Patients in Long-term Studies -- Panel Discussion III: Who is Concerned with Patient Welfare in Research? -- Concluding Remarks.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Cardiology.
|
| 650 |
|
0 |
|a Neurology .
|
| 650 |
|
0 |
|a Allergy.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Pharmacy.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Cardiology.
|
| 650 |
2 |
4 |
|a Neurology.
|
| 650 |
2 |
4 |
|a Allergology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Pharmacy.
|
| 700 |
1 |
|
|a Wolff, H.P.
|e editor.
|
| 700 |
1 |
|
|a Fleckenstein, A.
|e editor.
|
| 700 |
1 |
|
|a Philipp, Egon O.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-74615-4
|